All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
About the Lymphoma Hub
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma & CLL. Our aim is to enhance knowledge in lymphoma & CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage with treatment teams and researchers around the world.
VISION
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in lymphoma & CLL, to aid in treatment decisions and improve the lives of patients globally.
MISSION
The Lymphoma Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies, the Lymphoma Hub supports HCPs worldwide.
PARTNERSHIPS
The Lymphoma Hub was founded in partnership with the European Lymphoma Institute (ELI) in 2014. ELI is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training, and education. Together they look to define strategies to analyze and characterize lymphoma, common diagnostic procedures, and therapeutic standards, as well as to facilitate clinical and fundamental research. This leads to the advancement of lymphoma research, and works to guarantee equal access for all patients to the best possible care.
The European LeukemiaNet (ELN) is a publicly funded network of excellence, where clinicians and scientists improve therapy options for patients with leukemia worldwide. Together, they look to define strategies to improve leukemia characterization, its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This approach results in the advancement of leukemia research, and it supports equal access for all patients to the best possible care.
In 2025, the Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH) joins the Lymphoma Hub as a partner to promote global knowledge exchange and innovation in hematology. Representing over 5,000 professionals, ABHH is committed to advancing science, education, and equity in patient care through ethical leadership, multidisciplinary collaboration, and support for the next generation of specialists.
The Lymphoma Hub is partnering with the Hematology Society of Taiwan (HST), which works to disseminate and raise awareness of the latest scientific advances in hematology among specialists in the field. Established over 50 years ago, HST now consists of more than 500 members and 7 committees. The HST holds regular annual meetings and academic seminars to promote communication and knowledge exchange, supports collaborative hematology research between hospitals, and has established a formal training and accreditation system for hematologists in Taiwan.
BROUGHT TO YOU BY SES (SCIENTIFIC EDUCATION SUPPORT)
Independent medical education (IME), informed by patients, curated by world leaders, endorsed by expert societies. SES supports healthcare professionals and patients worldwide with up-to-date, accessible, and impactful educational content. Our hubs tackle information overload, providing a comprehensive central resource for healthcare professionals (HCPs) in specific disease areas that keep them up-to-date with the latest therapeutic news and world-leading opinions. Endorsed by expert societies, and a member of the gCMEp, our platforms ensure credibility and trust. By identifying and filling knowledge gaps in easily digestible formats, we facilitate continuous learning, leading to improved patient outcomes.
OUR HUBS
SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide.
THE SCIENTIFIC EDUCATION SUPPORT TEAM
The Lymphoma Hub is brought to you by Scientific Education Support (SES). SES loves nothing more than building communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options. The SES team takes care of the everyday management, content generation, and uploads on the Lymphoma Hub, assisting the Steering Committee in keeping the site as up to date as possible.
